[类风湿性关节炎患者的预后不良因素]
María Del Rocío Hernández-Morales1, Edna Elisa Garcia-Vences2, César Leonardo García-López3
1Universidad Anáhuac México Norte, Centro de Investigación en Ciencias de la Salud. Servicio de Inmunología Clínica y Alergia, SSA Puebla, México. ciaic.puebla@gmail.com.
Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
|December 20, 2025
概括
确定类风湿性关节炎 (RA) 预后不佳的预测因素至关重要. 抗素抗体 (ACCP) 的阳性,延迟的疾病修饰性抗风湿药物 (DMARD) 启动,以及吸烟显著增加了RA患者的患者数量.
科学领域:
- 风湿病学和免疫学
- 临床医学 临床医学
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性炎症性疾病,影响关节和潜在的其他器官.
- 识别预测不良预后的因素对于及时干预和管理至关重要.
- 了解这些因素可以帮助缓解RA患者的长期功能和限制生命的损伤.
研究的目的:
- 确定与类风湿性关节炎 (RA) 患者预后不佳相关的因素.
- 在现实临床环境中评估疾病进展和治疗升级的潜在预测因素.
主要方法:
- 一项观察性,分析性,纵向性队列研究进行了一年.
- 收集的数据包括患者人口统计学,并发症,吸烟状况,疾病活性评分 (DAS28),炎症标志物 (ESR,CRP),自身抗体 (ACCP,RF) 和骨质侵蚀的存在.
- 考克斯比例危险分析被用来确定预后不佳的预测因素.
主要成果:
- 分析了260名RA患者的队列.
- 确定的不良预后的关键预测因素是:抗素抗体 (ACCP) 阳性,延迟启动疾病修饰性抗风湿药物 (DMARD) 和目前的吸烟.
- 阳性ACCP患者的治疗升级风险增加了5.8倍,延迟开始DMARD与4.6倍的风险增加有关,而吸烟者则增加了7.7倍的风险.
结论:
- 确定RA中预后不佳的预测因子 (PPF) 仍然是一个重大的研究挑战.
- 早期识别这些因素对于预测治疗反应至关重要.
- 这允许及时进行干预,以尽量减少RA患者的功能限制和长期损伤.
相关概念视频
01:23Rheumatic Heart Disease I: Introduction
400
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
400
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
435
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
435
01:20Rheumatic Heart Disease IV: Nursing Management
243
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
243
01:24T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
01:21Rheumatic Heart Disease III: Medical Management
261
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
261
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
275
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
275